Comparison
Clascoterone vs Clascoterone
Breezula 5% scalp solution vs. Winlevi 1% cream — same molecule, different targets, protocols, and absorption profiles.
Clascoterone
Topical Androgen Receptor Antagonist
Clascoterone
Topical Androgen Receptor Antagonist
Effectiveness Profile
At a Glance
| Clascoterone | Clascoterone | |
|---|---|---|
| Type | Hair | Hair |
| Legal status | Rx-Only | Rx-Only |
| Half-life | 3–4 hours (plasma, after topical absorption) | Parent drug clears within hours; cortexolone metabolite ~4–6 hours |
| Preferred route | Topical solution (scalp), topical cream (acne) | Topical |
| Dose frequency | twice-daily | twice-daily |
| Beginner dose | 25–50 mg | 10–25 mg |
| Intermediate dose | 50–100 mg | 25–50 mg |
| Advanced dose | 100–150 mg | 50–100 mg |
| Cycle length | 24–104 wks | 12–52 wks |
| Bioavailability | 5% | — |
| Time to peak | 4h | 4h |
| Active duration | 12h | 12h |
| Storage | Room temperature, 20–25°C; protect from light. Hydroalcoholic solutions stored capped to prevent ethanol evaporation. | Room temperature (20–25°C); keep tightly closed, away from light |
| PCT required | No | No |
| Ancillaries required | No | No |
| Safe for women | Yes | Yes |
Verdict
Clascoterone (Breezula 5% solution) wins for: rigorous Phase 3 data for androgenetic alopecia, optimized for scalp penetration, higher clinical potency for slowing/reversing male-pattern hair loss, and a protocol tailored to hair retention. Clascoterone (Winlevi 1% cream) wins for: proven safety in acne protocols, ease of sourcing (FDA-approved), lower risk of local irritation, and utility as a topical anti-androgen for sebum control on face/back/shoulders.
Pick A or B?
Pick Clascoterone (Breezula 5%) if:
- The research goal is androgenetic alopecia (AGA) on the scalp
- A maximum-efficacy topical AR antagonist protocol is desired alongside minoxidil or oral/topical finasteride
- Hair retention on cycle, especially when 5AR inhibitors underperform (nandrolone, trenbolone, DHT orals)
- Documented Phase 3 trial data is critical in the protocol
- Tolerated higher local potency is needed for difficult cases
Pick Clascoterone (Winlevi 1% cream) if:
- The target is hormonal acne (face, back, chest) rather than scalp AGA
- Easier pharmaceutical-grade sourcing is a priority
- The protocol is focused on sebum reduction or mild AR blockade on non-scalp skin
- Lower risk of skin irritation or adverse effects is preferred
- There is off-label, experimental scalp use and 5% solutions are unavailable